Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept-Reference-Cited by-同舟云学术

Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept

Published:2017-09-27 Issue:56 Volume:8 Page:95824-95840
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Voissiere Aurélien¹,Weber Valérie¹,Gerard Yvain¹,Rédini Françoise²,Raes Florian³,Chezal Jean-Michel¹,Degoul Françoise¹,Peyrode Caroline¹,Miot-Noirault Elisabeth¹

Affiliation:

1. Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont-Ferrand, France

2. Nantes Atlantique Université, INSERM, UMR1238, Sarcomes osseux et remodelage des tissus calcifiés, Nantes, France

3. PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review on different approaches for tumor targeting using nanocarriers and recent developments with special focus on multifunctional approaches;Journal of Pharmaceutical Investigation;2022-07-28

2. Hypoxia-inducible factor (HIF)–mediated effects of the hypoxic niche in bone cancer;Bone Cancer;2022

3. In vitro three-dimensional cell cultures for bone sarcomas;Journal of Bone Oncology;2021-10

4. The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis;Cancers;2021-05-19

5. Relevance of the combination of external beam radiotherapy with the hypoxia-activated prodrug ICF05016 in an experimental model of extraskeletal myxoid chondrosarcoma;Investigational New Drugs;2020-09-18